Edwards Lifesciences Corporation(EW)Earnings, Financials & Key Ratios

EW•NYSE

$82.91

$47.8B mkt cap·45.3× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryCardiovascular and heart rhythm devices

AboutEdwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Show more

Revenue$6.07B+11.5%
EBITDA$1.79B+16.9%
Net Income$1.07B-74.3%
EPS (Diluted)1.83-73.7%
Gross Margin78.13%-1.7%
EBITDA Margin29.55%+4.8%
Operating Margin26.97%+6.4%
Net Margin17.69%-76.9%
ROE10.52%-78.8%
ROIC15.51%+4.9%
Debt/Equity0.07-1.9%

Analysis→Technical→

EW Key Insights

Edwards Lifesciences Corporation (EW) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 27.6%
✓FCF machine: 22.0% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 2.3% through buybacks
✓Healthy 5Y average net margin of 35.9%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

EW Price & Volume

Edwards Lifesciences Corporation (EW) stock price & volume — 10-year historical chart

Loading chart...

EW Growth Metrics

Edwards Lifesciences Corporation (EW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years9.3%

5 Years6.7%

3 Years4.08%

TTM11.21%

Profit CAGR

10 Years8.05%

5 Years5.45%

3 Years-10.98%

TTM-74.35%

EPS CAGR

10 Years9.33%

5 Years7.08%

3 Years-9.14%

TTM-73.74%

Return on Capital

10 Years20.94%

5 Years18.57%

3 Years15.48%

Last Year13.96%

EW Recent Earnings

Edwards Lifesciences Corporation (EW) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 9/12 qtrs (75%)●Beat Revenue 10/12 qtrs (83%)

Q2 2026Latest

Apr 23, 2026

EPS

$0.78

Est $0.73

+7.0%

Revenue

$1.6B

Est $1.6B

+3.2%

Q1 2026

Feb 10, 2026

EPS

$0.58

Est $0.62

-6.1%

Revenue

$1.6B

Est $1.5B

+1.5%

Q4 2025

Oct 30, 2025

EPS

$0.67

Est $0.60

+12.4%

Revenue

$1.6B

Est $1.5B

+3.7%

Q3 2025

Jul 24, 2025

EPS

$0.67

Est $0.62

+7.4%

Revenue

$1.5B

Est $1.5B

+3.0%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 23, 2026	$0.78vs $0.73+7.0%	$1.6Bvs $1.6B+3.2%
Q1 2026	Feb 10, 2026	$0.58vs $0.62-6.1%	$1.6Bvs $1.5B+1.5%
Q4 2025	Oct 30, 2025	$0.67vs $0.60+12.4%	$1.6Bvs $1.5B+3.7%
Q3 2025	Jul 24, 2025	$0.67vs $0.62+7.4%	$1.5Bvs $1.5B+3.0%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
MDTMedtronic plcDirect Competitor	99.73B	77.79	21.55	3.62%	13%	9.45%	5.2%	0.59
ABTAbbott LaboratoriesDirect Competitor	151.59B	87.18	11.41	4.59%	31.88%	27.26%	4.19%	0.32
BSXBoston Scientific CorporationDirect Competitor	83.2B	55.98	28.86	19.87%	14.4%	12.4%	4.4%	0.51
SYKStryker CorporationDirect Competitor	113.08B	295.25	35.15	11.16%	12.92%	15.04%	3.79%	0.66
ZBHZimmer Biomet Holdings, Inc.Direct Competitor	16.25B	83.01	23.38	7.2%	9.05%	5.77%	9.06%	0.59
NVCRNovoCure LimitedProduct Competitor	1.81B	15.88	-13.02	8.28%	-25.66%	-50.82%		0.85
ATRCAtriCure, Inc.Product Competitor	1.49B	29.44	-122.67	14.88%	-2.14%	-2.43%	3.24%	0.18
NTRANatera, Inc.Product Competitor	28.44B	206.77	-135.14	56.75%	-14.61%	-24.69%	0.24%	0.16

Compare EW vs Peers

Edwards Lifesciences Corporation (EW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MDT

Most directly comparable listed peer for EW.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare EW against a more recognizable public peer.

Peer Set

Compare Top 5

vs MDT, ABT, BSX, SYK

EW Income Statement

Edwards Lifesciences Corporation (EW) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	3.44B	3.72B	4.35B	4.39B	5.23B	5.38B	5.01B	5.44B	6.07B
Revenue Growth %	15.91%	8.37%	16.79%	0.88%	19.29%	2.86%	-6.92%	8.57%	11.55%
Cost of Goods Sold	882.9M	922.1M	1.16B	1.1B	1.23B	1.17B	1.04B	1.12B	1.33B
COGS % of Revenue	25.7%	24.77%	26.57%	25.06%	23.43%	21.69%	20.7%	20.54%	21.87%
Gross Profit	2.55B▲ 0%	2.8B▲ 9.7%	3.19B▲ 14.0%	3.29B▲ 3.0%	4.01B▲ 21.9%	4.22B▲ 5.2%	3.97B▼ 5.8%	4.32B▲ 8.8%	4.74B▲ 9.7%
Gross Margin %	74.3%	75.23%	73.43%	74.94%	76.57%	78.31%	79.3%	79.46%	78.13%
Gross Profit Growth %	18.28%	9.73%	14%	2.96%	21.88%	5.21%	-5.75%	8.79%	9.69%
Operating Expenses	1.54B	1.71B	1.99B	1.99B	2.4B	2.51B	2.55B	2.94B	3.1B
OpEx % of Revenue	44.9%	45.89%	45.88%	45.4%	45.79%	46.69%	50.81%	54.11%	51.17%
Selling, General & Admin	989.7M	1.09B	1.24B	1.23B	1.49B	1.57B	1.58B	1.79B	2.09B
SG&A % of Revenue	28.81%	29.18%	28.57%	28.06%	28.54%	29.12%	31.59%	32.89%	34.37%
Research & Development	552.6M	622.2M	752.7M	760.7M	903.1M	945.2M	962.9M	1.05B	1.08B
R&D % of Revenue	16.09%	16.71%	17.31%	17.34%	17.26%	17.56%	19.22%	19.36%	17.79%
Other Operating Expenses	0	0	0	0	0	0	0	101.1M	-59.9M
Operating Income	1.01B▲ 0%	1.09B▲ 8.1%	1.2B▲ 9.7%	1.3B▲ 8.2%	1.61B▲ 24.3%	1.7B▲ 5.7%	1.43B▼ 16.2%	1.38B▼ 3.4%	1.64B▲ 18.7%
Operating Margin %	29.4%	29.34%	27.55%	29.55%	30.78%	31.63%	28.49%	25.35%	26.97%
Operating Income Growth %	23.86%	8.14%	9.67%	8.19%	24.26%	5.71%	-16.16%	-3.4%	18.68%
EBITDA	1.09B	1.17B	1.31B	1.43B	1.77B	1.87B	1.57B	1.53B	1.79B
EBITDA Margin %	31.79%	31.42%	30.19%	32.63%	33.9%	34.73%	31.38%	28.2%	29.55%
EBITDA Growth %	23.15%	7.12%	12.21%	9.06%	23.91%	5.38%	-15.89%	-2.44%	16.88%
D&A (Non-Cash Add-back)	81.9M	77.4M	114.6M	135.4M	163.3M	166.8M	144.9M	155.2M	156.6M
EBIT	1.06B	794.8M	1.19B	938.9M	1.73B	1.79B	1.39B	1.57B	1.27B
Net Interest Income	-2.9M	-1.4M	4.9M	1.2M	-7.4M	9.3M	49.6M	100.5M	148.4M
Interest Income	20.3M	32M	32.2M	23.4M	17.4M	35.5M	67.2M	120.3M	148.4M
Interest Expense	23.2M	33.4M	27.3M	22.2M	24.8M	26.2M	17.6M	19.8M	0
Other Income/Expense	24.8M	-330.9M	-31.4M	-379.3M	91.6M	65M	-54.9M	169.4M	-363.3M
Pretax Income	1.03B▲ 0%	761.4M▼ 26.4%	1.17B▲ 53.2%	916.7M▼ 21.4%	1.7B▲ 85.7%	1.77B▲ 3.8%	1.37B▼ 22.3%	1.55B▲ 12.8%	1.27B▼ 17.8%
Pretax Margin %	30.13%	20.45%	26.83%	20.9%	32.53%	32.84%	27.39%	28.46%	20.98%
Income Tax	451.3M	39.2M	119.6M	93.3M	198.9M	245.5M	152.4M	152.1M	216.9M
Effective Tax Rate %	43.61%	5.15%	10.25%	10.18%	11.69%	13.89%	11.1%	9.82%	17.04%
Net Income	622.1M▲ 0%	722.2M▲ 16.1%	1.05B▲ 45.0%	823.4M▼ 21.3%	1.5B▲ 82.5%	1.52B▲ 1.3%	1.4B▼ 7.9%	4.17B▲ 197.7%	1.07B▼ 74.3%
Net Margin %	18.11%	19.4%	24.08%	18.77%	28.73%	28.28%	27.99%	76.75%	17.69%
Net Income Growth %	9.24%	16.09%	44.96%	-21.35%	82.55%	1.25%	-7.85%	197.68%	-74.28%
Net Income (Continuing)	583.6M	722.2M	1.05B	823.4M	1.5B	1.52B	1.22B	1.4B	1.06B
Discontinued Operations	0	0	0	0	0	0	179.4M	2.77B	13.4M
Minority Interest	0	0	0	0	0	0	69.4M	64.5M	0
EPS (Diluted)	0.96▲ 0%	1.13▲ 17.7%	1.64▲ 45.1%	1.30▼ 20.7%	2.38▲ 83.1%	2.44▲ 2.5%	2.30▼ 5.7%	6.97▲ 203.0%	1.83▼ 73.7%
EPS Growth %	10.34%	17.71%	45.13%	-20.73%	83.08%	2.52%	-5.74%	203.04%	-73.74%
EPS (Basic)	0.98	1.15	1.68	1.32	2.41	2.46	2.31	6.98	1.84
Diluted Shares Outstanding	647.7M	640.8M	636.6M	631.9M	631.2M	624.2M	609.4M	599.3M	585.8M
Basic Shares Outstanding	632.7M	627.6M	624.9M	622.6M	623.3M	619M	606.7M	597.7M	584.8M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

EW Balance Sheet

Edwards Lifesciences Corporation (EW) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	2.53B	2.29B	2.98B	3.09B	3.18B	3.1B	4.04B	6.29B	6.74B
Cash & Short-Term Investments	1.34B	956.5M	1.52B	1.4B	1.47B	1.22B	1.63B	3.98B	4.23B
Cash Only	818.3M	714.1M	1.18B	1.18B	862.8M	769M	1.13B	3.05B	2.94B
Short-Term Investments	519.2M	242.4M	337.8M	219.4M	604M	446.3M	500.5M	930.7M	1.29B
Accounts Receivable	479.3M	537.3M	599.1M	602.8M	664.9M	699.1M	828.1M	727.4M	912.1M
Days Sales Outstanding	50.93	52.68	50.29	50.16	46.38	47.41	60.33	48.81	54.87
Inventory	554.9M	607M	640.9M	802.3M	726.7M	875.5M	903.5M	1.09B	1.13B
Days Inventory Outstanding	229.4	240.27	202.48	266.46	216.37	273.78	317.92	354.94	309.79
Other Current Assets	116.9M	131.8M	168M	208.2M	237.1M	195.9M	542.5M	374.4M	338.8M
Total Non-Current Assets	3.16B	3.04B	3.5B	4.15B	5.32B	5.2B	5.33B	6.77B	6.96B
Property, Plant & Equipment	679.7M	867.5M	1.14B	1.49B	1.64B	1.73B	1.68B	1.78B	1.91B
Fixed Asset Turnover	5.05x	4.29x	3.81x	2.95x	3.19x	3.12x	2.99x	3.05x	3.17x
Goodwill	1.13B	1.11B	1.17B	1.17B	1.17B	1.16B	1.15B	1.78B	1.77B
Intangible Assets	468M	343.2M	336.5M	331.4M	323.6M	285.2M	399.4M	1.18B	1.13B
Long-Term Investments	567M	506.3M	585.5M	801.6M	1.83B	1.24B	583.9M	307.9M	773.9M
Other Non-Current Assets	108.9M	33.6M	101.8M	119.6M	110.8M	299.1M	774.3M	732.4M	234.9M
Total Assets	5.7B▲ 0%	5.32B▼ 6.5%	6.49B▲ 21.9%	7.24B▲ 11.5%	8.5B▲ 17.5%	8.29B▼ 2.5%	9.36B▲ 12.9%	13.06B▲ 39.4%	13.7B▲ 4.9%
Asset Turnover	0.60x	0.70x	0.67x	0.61x	0.62x	0.65x	0.54x	0.42x	0.44x
Asset Growth %	26.31%	-6.54%	21.87%	11.54%	17.49%	-2.47%	12.91%	39.43%	4.92%
Total Current Liabilities	1.4B	876.6M	902.4M	893.9M	1.03B	1.02B	1.2B	1.51B	1.81B
Accounts Payable	116.6M	134M	180.4M	196.5M	204.5M	201.9M	186.6M	197.4M	227.5M
Days Payables Outstanding	48.2	53.04	56.99	65.26	60.89	63.14	65.66	64.48	62.58
Short-Term Debt	598M	0	0	0	0	0	0	0	24.5M
Deferred Revenue (Current)	0	0	0	0	0	0	0	53.7M	27.2M
Other Current Liabilities	349.1M	434M	338.9M	290.5M	342.7M	305M	530.2M	442.7M	874.5M
Current Ratio	1.81x	2.61x	3.31x	3.46x	3.08x	3.03x	3.38x	4.18x	3.72x
Quick Ratio	1.41x	1.92x	2.60x	2.56x	2.38x	2.17x	2.62x	3.45x	3.09x
Cash Conversion Cycle	232.12	239.91	195.78	251.36	201.86	258.05	312.59	339.27	302.08
Total Non-Current Liabilities	1.3B	1.31B	1.44B	1.77B	1.63B	1.46B	1.45B	1.49B	1.55B
Long-Term Debt	438.4M	593.8M	594.4M	595M	595.7M	596.3M	597M	597.7M	598.3M
Capital Lease Obligations	0	0	58.9M	72.7M	69.1M	69.5M	65.2M	78.9M	82.6M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	851.8M	712.9M	784.1M	1.1B	969.6M	797.6M	786.2M	810.6M	865M
Total Liabilities	2.7B	2.18B	2.34B	2.66B	2.67B	2.49B	2.64B	2.99B	3.36B
Total Debt	1.04B	593.8M	678.8M	694.9M	690.3M	691.3M	685.1M	700M	705.4M
Net Debt	218.1M	-120.3M	-500.3M	-488.3M	-172.5M	-77.7M	-447.2M	-2.35B	-2.23B
Debt / Equity	0.35x	0.19x	0.16x	0.15x	0.12x	0.12x	0.10x	0.07x	0.07x
Debt / EBITDA	0.95x	0.51x	0.52x	0.49x	0.39x	0.37x	0.44x	0.46x	0.39x
Net Debt / EBITDA	0.20x	-0.10x	-0.38x	-0.34x	-0.10x	-0.04x	-0.28x	-1.53x	-1.25x
Interest Coverage	45.61x	23.80x	43.73x	42.29x	69.63x	68.46x	78.98x	79.19x	-
Total Equity	2.99B▲ 0%	3.14B▲ 4.9%	4.15B▲ 32.1%	4.57B▲ 10.3%	5.84B▲ 27.6%	5.81B▼ 0.5%	6.72B▲ 15.7%	10.06B▲ 49.8%	10.34B▲ 2.7%
Equity Growth %	14.35%	4.87%	32.09%	10.27%	27.58%	-0.5%	15.72%	49.76%	2.73%
Book Value per Share	4.62	4.90	6.52	7.24	9.25	9.30	11.03	16.79	17.65
Total Shareholders' Equity	2.99B	3.14B	4.15B	4.57B	5.84B	5.81B	6.65B	10B	10.34B
Common Stock	212M	215.2M	218.1M	636.4M	642M	646.3M	650.5M	654.8M	658.7M
Retained Earnings	2B	2.69B	3.74B	4.57B	6.07B	7.59B	8.99B	13.17B	14.24B
Treasury Stock	-252.1M	-1.02B	-1.28B	-1.9B	-2.42B	-4.14B	-5.02B	-6.19B	-7.09B
Accumulated OCI	-132.7M	-138.5M	-156M	-161.1M	-157.7M	-254.9M	-242.8M	-244.5M	-238.3M
Minority Interest	0	0	0	0	0	0	69.4M	64.5M	0

EW Cash Flow Statement

Edwards Lifesciences Corporation (EW) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	1B	926.8M	1.18B	1.05B	1.73B	1.22B	895.8M	542.3M	1.6B
Operating CF Margin %	29.13%	24.9%	27.13%	24.04%	33.1%	22.63%	17.88%	9.97%	26.29%
Operating CF Growth %	42.06%	-7.38%	27.26%	-10.61%	64.29%	-29.67%	-26.47%	-39.46%	194.15%
Net Income	583.6M	722.2M	1.05B	823.4M	1.5B	1.52B	1.4B	4.17B	1.07B
Depreciation & Amortization	81.9M	77.4M	89.3M	107.2M	134.8M	139.6M	144.9M	155.2M	156.6M
Stock-Based Compensation	61.6M	71M	81.3M	92.6M	109.3M	126.8M	139.4M	162.3M	158.1M
Deferred Taxes	17.8M	-27.3M	12.1M	-49.4M	-41.4M	-254.5M	-272.1M	-323.4M	-117.6M
Other Non-Cash Items	21.6M	126.1M	154.1M	38.3M	-119M	105.8M	7.5M	-3.36B	174.1M
Working Capital Changes	234.2M	-42.6M	-204.3M	42.2M	145.3M	-421.4M	-526.3M	-259.3M	154.6M
Change in Receivables	-3.9M	-13M	-94.8M	283.9M	-112.4M	-84.1M	-141.2M	121.2M	-23M
Change in Inventory	-124M	-65.7M	-105.4M	-120.6M	19M	-213.4M	-289M	-256.1M	50.7M
Change in Payables	85.2M	192.5M	-63.5M	-84.5M	195.2M	-21.4M	146M	89.5M	395.1M
Cash from Investing	-647.2M	76.7M	-595.8M	-531.1M	-1.72B	252.3M	173.8M	2.31B	-712.9M
Capital Expenditures	-175.5M	-241.7M	-278.4M	-407.3M	-329.8M	-264.8M	-266.3M	-282.4M	-260.2M
CapEx % of Revenue	5.11%	6.49%	6.4%	9.29%	6.3%	4.92%	5.32%	5.19%	4.29%
Acquisitions	-184.6M	-6.2M	-100.2M	407.3M	329.8M	0	-95.2M	-1.06B	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-43.1M	-4.8M	-24M	-446.4M	-359.3M	-63.1M	-75M	3.75B	-195.7M
Cash from Financing	-473.2M	-1.1B	-115.6M	-486.9M	-356.3M	-1.58B	-711M	-983M	-956.8M
Debt Issued (Net)	176.3M	-437.3M	-10M	-800K	-1.8M	-200K	-300K	0	0
Equity Issued (Net)	-763.3M	-795.5M	-263.3M	-625.4M	-512.8M	-1.73B	-879.6M	-1.16B	-719.3M
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-763.3M	-795.5M	-263.3M	-625.4M	-512.8M	-1.73B	-879.6M	-1.16B	-893.4M
Other Financing	113.8M	131.6M	157.7M	139.3M	158.3M	142.8M	168.9M	176.4M	-237.5M
Net Change in Cash	-111.8M▲ 0%	-104.2M▲ 6.8%	465M▲ 546.3%	15.8M▼ 96.6%	-332.8M▼ 2206.3%	-94.8M▲ 71.5%	375.4M▲ 496.0%	1.91B▲ 409.0%	-119.3M▼ 106.2%
Free Cash Flow	825.2M▲ 0%	685.1M▼ 17.0%	901M▲ 31.5%	647M▼ 28.2%	1.4B▲ 116.7%	953.4M▼ 32.0%	629.5M▼ 34.0%	289.9M▼ 53.9%	1.33B▲ 360.5%
FCF Margin %	24.02%	18.4%	20.72%	14.75%	26.8%	17.71%	12.56%	5.33%	22%
FCF Growth %	69.45%	-16.98%	31.51%	-28.19%	116.74%	-32.01%	-33.97%	-53.95%	360.5%
FCF per Share	1.27	1.07	1.42	1.02	2.22	1.53	1.03	0.48	2.28
FCF Conversion (FCF/Net Income)	1.61x	1.28x	1.13x	1.28x	1.15x	0.80x	0.64x	0.13x	1.49x
Interest Paid	19.9M	30.1M	19.9M	19.9M	20.2M	19.3M	19.9M	19.6M	0
Taxes Paid	143.7M	223.7M	61.5M	197.9M	182.5M	504.1M	470.1M	1.2B	0

EW Key Ratios

Edwards Lifesciences Corporation (EW) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	22.24%	22.16%	23.54%	28.73%	18.88%	28.88%	26.14%	22.39%	49.75%	10.52%
Return on Invested Capital (ROIC)	25%	26.47%	26.29%	26.95%	25.14%	24.78%	22.41%	17.84%	14.78%	15.51%
Gross Margin	72.81%	74.3%	75.23%	73.43%	74.94%	76.57%	78.31%	79.3%	79.46%	78.13%
Net Margin	19.22%	18.11%	19.4%	24.08%	18.77%	28.73%	28.28%	27.99%	76.75%	17.69%
Debt / Equity	0.31x	0.35x	0.19x	0.16x	0.15x	0.12x	0.12x	0.10x	0.07x	0.07x
Interest Coverage	41.99x	45.61x	23.80x	43.73x	42.29x	69.63x	68.46x	78.98x	79.19x	-
FCF Conversion	1.24x	1.61x	1.28x	1.13x	1.28x	1.15x	0.80x	0.64x	0.13x	1.49x
Revenue Growth	18.85%	15.91%	8.37%	16.79%	0.88%	19.29%	2.86%	-6.92%	8.57%	11.55%

EW SEC Filings & Documents

Edwards Lifesciences Corporation (EW) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 23, 2026·SEC

Material company update

Feb 10, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Feb 25, 2026·SEC

FY 2025

Feb 28, 2025·SEC

10-Q Quarterly Reports

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

FY 2025

May 6, 2025·SEC

EW Frequently Asked Questions

Edwards Lifesciences Corporation (EW) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Edwards Lifesciences Corporation (EW) reported $6.07B in revenue for fiscal year 2025. This represents a 570% increase from $905.0M in 1999.

Edwards Lifesciences Corporation (EW) grew revenue by 11.5% over the past year. This is steady growth.

Yes, Edwards Lifesciences Corporation (EW) is profitable, generating $1.07B in net income for fiscal year 2025 (17.7% net margin).

Dividend & Returns

Edwards Lifesciences Corporation (EW) has a return on equity (ROE) of 10.5%. This is reasonable for most industries.

Edwards Lifesciences Corporation (EW) generated $1.33B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More EW

Edwards Lifesciences Corporation (EW) financial analysis — history, returns, DCA and operating performance tools

Full EW Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Edwards Lifesciences Corporation(EW)Earnings, Financials & Key Ratios

EW Key Insights

✓Strengths

✗Weaknesses

EW Price & Volume

EW Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

EW Recent Earnings

EW Peer Comparison

Compare EW vs Peers

vs MDT

vs JNJ

Compare Top 5

EW Income Statement

EW Balance Sheet

EW Cash Flow Statement

EW Key Ratios

EW SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

EW Frequently Asked Questions

Explore More EW

Full EW Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation